Mitchell Chan - 02 Jan 2025 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Reporting relationship: Chief Financial Officer
Issuer ticker: RGNX
Reported as of: 02 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jan 2025, 16:59:14 UTC
Prior SEC filing: 18 Sep 2024
Next SEC filing: 01 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Patrick J. Christmas as attorney-in-fact

Key filing fact

Mitchell Chan filed Form 4 for REGENXBIO Inc. (RGNX) on 06 Jan 2025.

Key facts

This page summarizes Mitchell Chan's Form 4 filing for REGENXBIO Inc. (RGNX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Jan 2025, 16:59.

Change

Previous filing in this sequence was filed on 18 Sep 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RGNX transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $0
Shares: +62,547
Change %
Price: $0.000000
Shares after: 62,547
Date: 02 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 62,547
Exercise price: $7.86
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer.